Edmonson J H, Johnson P S, Wieand H S, Malkasian G D, Cullinan S A, Brown L D, Mailliard J A, Jefferies J A
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
Am J Clin Oncol. 1988 Apr;11(2):149-51. doi: 10.1097/00000421-198804000-00012.
In a randomized phase II trial of two cisplatin-based chemotherapy regimens, 45 patients with advanced cervical carcinoma received a combination of bleomycin, cyclophosphamide, doxorubicin, and cisplatin (BCAP), and 45 others received bleomycin plus cisplatin (BP). BCAP was repeated every 4 weeks, and BP was given at 3-week intervals. Although 19 of 43 (44%) evaluable patients receiving BCAP and 16 of 42 (38%) evaluable patients receiving BP experienced tumor regression, only 22% of those receiving BCAP and 21% of those on BP survived 1 year after beginning treatment. Among bidimensionally measurable patients, 15 of 27 (56%) and 8 of 25 (32%) receiving BCAP and BP, respectively, achieved tumor regression. One patient died of bleeding resulting from severe myelosuppression on BCAP, and two others succumbed to pulmonary toxicity of bleomycin on the BP regimen. Although active against cervical carcinoma, these regimens have limited therapeutic value at this advanced stage of the disease.
在一项针对两种基于顺铂的化疗方案的随机II期试验中，45例晚期宫颈癌患者接受了博来霉素、环磷酰胺、阿霉素和顺铂联合治疗（BCAP），另外45例患者接受了博来霉素加顺铂治疗（BP）。BCAP每4周重复一次，BP每3周给药一次。虽然接受BCAP治疗的43例可评估患者中有19例（44%）和接受BP治疗的42例可评估患者中有16例（38%）出现肿瘤消退，但开始治疗后，接受BCAP治疗的患者中只有22%存活1年，接受BP治疗的患者中这一比例为21%。在可进行二维测量的患者中，接受BCAP和BP治疗的患者分别有27例中的15例（56%）和25例中的8例（32%）实现了肿瘤消退。1例患者死于BCAP治疗导致的严重骨髓抑制引起的出血，另外2例患者死于BP方案中博来霉素的肺毒性。尽管这些方案对宫颈癌有效，但在疾病的这一晚期阶段，其治疗价值有限。
